Immunity, inflammation, and bipolar disorder: Diagnostic and therapeutic implications

Current Psychiatry Reports

Volumn 15, Issue 9, 2013, Pages

  Hamdani, Nora ^a,b,c,e,f   Doukhan, Raphael ^b   Kurtlucan, Ozlem ^b   Tamouza, Ryad ^d,e   Leboyer, Marion ^a,b,c,e  

^a FACULTÉ DE MÉDECINE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c INSERM U955   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e FONDATION FONDAMENTAL   (France)

^f Hopital Albert Chenevier   (France)

Author keywords

Auto antibody; Bipolar disorder; Comorbid substance use disorder; CRP; Cytokines; Endogenous retroviruses; Immuno genetic; Medical comorbidity; Psychiatry

Indexed keywords

AMANTADINE; C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; REBOXETINE; ANTIDEPRESSANT AGENT;

ARTICLE; AUTOIMMUNE DISEASE; BIPOLAR DISORDER; COMORBIDITY; DISEASE ASSOCIATION; ELECTROCONVULSIVE THERAPY; GENETIC MARKER; HLA SYSTEM; HUMAN; IMMUNITY; INFLAMMATION; PERSONALIZED MEDICINE; AUTOIMMUNITY; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; AUTOIMMUNITY; BIPOLAR DISORDER; C-REACTIVE PROTEIN; COMORBIDITY; CYTOKINES; HUMANS; INFLAMMATION;

EID: 84881416732     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0387-y     Document Type: Article

References (89)

1. Bauer MS, Altshuler L, Evans DR, et al. Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord. 2005;85:301-15. (Pubitemid 40386514)
2. • Leboyer M, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry. 2010;71(12):1689-95. An original paper with useful advices.
3. • Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;141(1):1-10. A good review of comorbid diseases in bipolar disorder.
4. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368-73. (Pubitemid 39345287)
5. Kupfer DJ. The increasing medical burden in medical disorder. JAMA. 2005;20:2528-30. (Pubitemid 40705735)
6. Goldstein BI, Kem DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078-90.
7. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10:788-97.
8. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147-56.
9. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-50. (Pubitemid 32979302)
10. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23(1):40-7.
11. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S-60S.
12. Laaksonen D, Lakka HM, Niskanen L, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070-7. (Pubitemid 35396938)
13. Lakka TA, Niskanen LK, Kumpusalo E, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16. (Pubitemid 35403784)
14. Mc Intyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabete mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17(2):83-93. (Pubitemid 40967131)
15. Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci. 2011;65:47-54.
16. Miller BJ, Mellor A, Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun. 2013;31:82-9.
17. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20:131-7. (Pubitemid 352009283)
18. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? 2009;11(6):475-480.
19. Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008;110(1-2):149-55.
20. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68(6):917-23. (Pubitemid 47015492)
21. Johannessen L, Strudsholm U, Foldager L, Munk-Jørgensen P. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. 2006;95:13-7. (Pubitemid 46110785)
22. Angst F, Stassenm HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow up of 34-38 years. J Affect Disord. 2002;68:167-81. (Pubitemid 34628324)
23. Perris C, d'Ellia G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand. 1996;164:172-89.
24. Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry. 1980;37(9):979-83. (Pubitemid 10004695)
25. • Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638-46. Good topic for autoimmunity in bipolar disorder with interesting data.
26. Vonk R, Van der Schot AC, Kahn RS, et al. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry. 2007;62(2):135-40. (Pubitemid 46963249)
27. Cassidy F, Ahearm E, Carroll BJ. Elevated frequency of diabete mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156(9):1417-20. (Pubitemid 29416540)
28. Kupka RW, Regeer EJ. Bipolar mood disorders. Ned Tijdschr Geneeskd. 2007;151(41):2256-60.
29. Severance EG, Dickerson FB, Halling M, et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res. 2010;118(1-3):240-7.
30. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 2009;48:111-36.
31. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006;119(2):166.e17-28. (Pubitemid 43151486)
32. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171-86.
33. Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry. 2010;197:372-7.
34. Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175-9. (Pubitemid 34678878)
35. Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):370-2. (Pubitemid 46209415)
36. Dickerson F, Stallings C, Origoni A, et al. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952-5. (Pubitemid 46660310)
37. De Berardis D, Conti CM, Campanella D, Carano A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008;21(2):319-24. (Pubitemid 351988393)
38. Cunha AB, Andreazza AC, Gomes FA, Frey BN, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(5):300-4.
39. Tsai SY, Chen KP, Yang YY, et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 1999;45(8):989-94. (Pubitemid 29219619)
40. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1-3):91-5. (Pubitemid 350064526)
41. Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596-602. (Pubitemid 47365627)
42. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2-3):263-7. (Pubitemid 43183536)
43. Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 1999;33(4):335-40. (Pubitemid 29267636)
44. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1-2):110-6.
45. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun. 2009;23(8):1079-82.
46. Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743-53. (Pubitemid 350042410)
47. Mollace V, Muscoli C, Masini E, et al. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev. 2005;57(2):217-52. (Pubitemid 41043885)
48. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263-71.
49. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384-92.
50. Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vazquez GH, Vieta E, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1366-71.
51. Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9(7):671-8. (Pubitemid 350042401)
52. • Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144(1-2):16-27. doi: 10.1016/j.jad.2012.06.010. A recent meta-analysis to assess the role of cytokines in bipolar disorder.
53. Pawelec G, Barnett Y, Forsey R, et al. T cells and aging. Front Biosci. 2002;7:d1056-183.
54. Czerski PM, Rybakowski F, Kapelski P, Rybakowski JK, et al. Association of tumor necrosis factor -308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology. 2008;57(1-2):88-94. (Pubitemid 351859339)
55. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20(5 Suppl 27):S1-S13.
56. Hwang JP, Tsai SJ, Hong CJ, et al. Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. Neuromolecular Med. 2009;11(4):322-7.
57. Papiol S, Molina V, Desco M, et al. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). Genes Brain Behav. 2008;7(7):796-801.
58. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 65(4):395-407.
59. Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol. 2005;14(3-4):175-82. (Pubitemid 40848523)
60. Biederman J, Keller M, Lavori P, et al. HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry. 1987;22(2):221-4. (Pubitemid 17222136)
61. Sorokina TT, Evsegneev RA, Levin VI, Semenov GV. Features of the distribution of HLA-antigens among patients with endogenous psychose. Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(6):885-8.
62. • Debnath M, Busson M, Jamain S, et al. The HLA-G low expressor genotype is associated with protection against bipolar disorder. Hum Immunol. 2013;74(5):593-7. Recent data for the implication of the HLAG in bipolar disorder.
63. Biederman J, Keller M, Lavori P, Harmatz J, Knee D, Dubey D, et al. HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry. 1987;22(2):221-4. (Pubitemid 17222136)
64. Bozikas VP, Anagnostouli MC, Petrikis P, et al. Familial bipolar disorder and multiple sclerosis: a three-generation HLA family study. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):835-9. (Pubitemid 36966766)
65. Kaminsky Z, Tochigi M, Jia P, et al. A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Mol Psychiatry. 2012;17(7):728-40. doi: 10.1038/mp.2011.64.
66. Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2(6):reviews 1017.
67. Venter A. New protein blocks HIV. Trends Microbiol. 2001;9(3):110.
68. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001;15(4):579-89. (Pubitemid 33016443)
69. • Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148(2-3):444-8. Recent data presenting the link between infectious agents and bipolar disorder.
70. Frank O, Giehl M, Zheng C, Hehlmann R, Leib-Mosch C, Seifarth W. Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorder. J Virol. 2005;79(17):10890-901. (Pubitemid 41170631)
71. Weis S, Llenos IC, Sabunciyan S, et al. Reduced expression of human endogenous retrovirus (HERV)-W GAG protein in the cingulate gyrus and hippocampus in schizophrenia, bipolar disorder, and depression. J Neural Transm. 2007;114(5):645-55. (Pubitemid 46664044)
72. Perron H, Mekaoui L, Bernard C, Veas F, Stefas I, Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol Psychiatry. 2008;64(12):1019-23.
73. • Perron H, Hamdani N, Faucard R, et al. Molecular characteristics of Human Endogenous Retrovirus type-W (HERV-W) in schizophrenia and bipolar disorder. Transl Psychiatry. 2012. doi: 10.1038/tp.2012.125. The only study involving the HERV in bipolar disorder.
74. Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, et al. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci. 2004;7(10):1088-95. (Pubitemid 41184449)
75. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683-94. (Pubitemid 30249643)
76. Kronfol Z, LeMay L, Nair M, Kluger M. Electroconvulsive therapy increases plasma levels of interleukin-6. Ann NY Acad Sci. 1990;594:463-5. (Pubitemid 20298267)
77. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82(2):309-13. (Pubitemid 39370835)
78. Maes M, Calabrese J, Jayathilake K, Meltzer HY. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res. 1997;71(2):67-76. (Pubitemid 27281611)
79. Rapaport MH. Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord. 1994;32(3):149-56. (Pubitemid 24341678)
80. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123-7. (Pubitemid 27196534)
81. Bubak-Satora M, Skowron-Cendrzak A, Kubera M. The effect of lithium chloride treatment on cell-mediated immunity in mice. Folia Biol (Krakow). 1991;39(1-4):21-4.
82. Krause I, Cohen J, Blank M, et al. Distribution of two common idiotypes of anticardiolipin antibodies in sera of patients with primary antiphospholipid syndrome, systemic lupus erythematosus and monoclonal gammopathies. Lupus. 1992;1(2):91-6.
83. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003;62(3):237-44. (Pubitemid 36775365)
84. Vale S, Espejel MA, Dominguez JC. Amantadine in depression. Lancet. 1971;2(7721):437.
85. Bode L, Durrwald R, Rantam FA, et al. First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry. 1996;1(3):200-12. (Pubitemid 126441293)
86. Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord. 2000;2(1):65-70.
87. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry. 1999;32(2):47-55. (Pubitemid 29197549)
88. Muller N, Schwarz MJ, Dehning S, Douhe A, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680-4. (Pubitemid 43989814)
89. Casolini P, Catalani A, Zuena AR, Angelucci L. Inhibition of COX-2 reduce the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res. 2002;68(3):337-43.